Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatm... Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriasis . The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. 詳細を表示
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0002 | -66.6666666667 | 0.0003 | 0.0003 | 1.0E-6 | 6700 | 0.0003 | CS |
| 4 | 9.9E-5 | 9900 | 1.0E-6 | 0.0003 | 1.0E-6 | 3560 | 0.00028236 | CS |
| 12 | 0 | 0 | 0.0001 | 0.0003 | 1.0E-6 | 2014 | 0.00014501 | CS |
| 26 | 0 | 0 | 0.0001 | 0.0005 | 1.0E-6 | 2939 | 0.00023082 | CS |
| 52 | -0.0004 | -80 | 0.0005 | 0.0006 | 1.0E-6 | 3914 | 0.00039698 | CS |
| 156 | -0.1604 | -99.937694704 | 0.1605 | 0.2475 | 1.0E-6 | 33343 | 0.04856964 | CS |
| 260 | -0.1604 | -99.937694704 | 0.1605 | 0.2475 | 1.0E-6 | 33343 | 0.04856964 | CS |
NeoSunTzu
6分前
The_Golden_One
8分前
farml1234
12分前
satter
18分前
MONTI KING
18分前
WhenLambo
19分前
Truthsocial
28分前
Whalatane
29分前
againstallodds
31分前
jour_trader
36分前
tmcfo
39分前
ご覧いただいた銘柄が下記のボックス内に表示されますので、過去閲覧した銘柄情報に簡単にアクセスすることができます。
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
すでにアカウントをお持ちですか? サインイン
アカウントをお持ちでないですか? 登録
登録することで、ADVFN の 利用規約 を読み、理解し、同意したこと、および私が個人投資家であることを確認します。